8XB Stock Overview
A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biocartis Group NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.26 |
| 52 Week High | €0.76 |
| 52 Week Low | €0.26 |
| Beta | 1.38 |
| 11 Month Change | 0% |
| 3 Month Change | 1.17% |
| 1 Year Change | -47.09% |
| 33 Year Change | -94.25% |
| 5 Year Change | -97.38% |
| Change since IPO | -98.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8XB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -0.4% |
| 1Y | -47.1% | -7.1% | 7.1% |
Return vs Industry: 8XB underperformed the German Medical Equipment industry which returned 9.8% over the past year.
Return vs Market: 8XB underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| 8XB volatility | |
|---|---|
| 8XB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8XB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8XB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 526 | Roger Moody | www.biocartisgroupnv.be |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
Biocartis Group NV Fundamentals Summary
| 8XB fundamental statistics | |
|---|---|
| Market cap | €27.24m |
| Earnings (TTM) | -€67.87m |
| Revenue (TTM) | €60.82m |
0.4x
P/S Ratio-0.4x
P/E RatioIs 8XB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8XB income statement (TTM) | |
|---|---|
| Revenue | €60.82m |
| Cost of Revenue | €65.51m |
| Gross Profit | -€4.69m |
| Other Expenses | €63.18m |
| Earnings | -€67.87m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | -7.71% |
| Net Profit Margin | -111.58% |
| Debt/Equity Ratio | -257.9% |
How did 8XB perform over the long term?
See historical performance and comparison